Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenSpera has announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.
Subscribe to our email newsletter
The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed or recurred after at least one other treatment.
GenSpera CEO Dr Craig Dionne noted the GBM trial constitutes another milestone in the company’s plan to develop G-202 in multiple cancer indications.
"We are particularly pleased to collaborate with Dr. Kesari and his colleagues, who have been so instrumental in developing the rationale for potential utility of G-202 in GBM and other brain tumors," Dr Dionne added.
The Phase II trial will treat up to 34 patients with recurrent or progressive glioblastoma who have undergone at least one prior treatment regimen that must include surgery and/or radiotherapy.
The primary endpoint of the trial is six-month progression-free survival after at least two cycles of treatment.